SANDY, Utah--(BUSINESS WIRE)--OmniLytics, Inc., formerly of Salt Lake City, Utah, today announced that it has moved its Corporate headquarters and operations 20 miles south to Sandy, Utah. This move dramatically increases the Company's footprint and provides access to over 60,000 square feet of state-of-the-art laboratories and production space, which allows the Company to continue to expand its market leading manufacturing presence while simultaneously increasing capacity within its analytical, research and development laboratories.
OmniLytics produced, processed and shipped nearly 100,000 liters of customized bacteriophage product during 2010 through Contract Manufacturing relationships, as well as directly to end customers. Justin Reber, President and CEO of OmniLytics, stated, The global need for bacterial control solutions has received heightened attention over the past several years, and OmniLytics is committed to meet this increased demand. This move not only significantly increases our manufacturing capabilities, but also provides the potential for future expansion onto an additional seven acres of undeveloped property acquired adjacent to the four acre, two building campus. This investment further reinforces OmniLytics' commitment to provide safe, natural bacteriophage solutions on a global level by continuing its leadership role in bacteriophage research and commercialization.
A master plan for the production facility is also near completion as part of this expansion project, providing advanced equipment that can support the production and delivery of millions of liters of final product on an annual basis. OmniLytics sees this move as a critical step in meeting the burgeoning demands of global bacteriophage solutions.
About OmniLytics, Inc.
OmniLytics is a bacteriophage company focused on developing safe, natural solutions for infectious disease control. OmniLytics was the first company to work with any United States regulatory agency on a submission claiming bacteriophage as the active ingredient, and with the approval of its AgriPhage product in 2005, it became the first company to receive a registration from any US regulatory body. OmniLytics continues to expand its research and development of bacteriophage solutions for control of microorganisms in agricultural, food & water, industrial, pharmaceutical, and defense markets. OmniLytics' proprietary formulas and processes optimize the use of natural bacteriophage for commercial applications. For more information about OmniLytics, visit www.omnilytics.com.